POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

NEXT STORY
Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia
PREV STORY
Orphan Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) – other company programmes in AD continue

The Alzheimer's Prevention Initiative (API) study of crenezumab in familial Alzheimer's disease continues Roche ...

author_avatar
NASDAQ Market News

Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association

author_avatar
NASDAQ Market News

Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments

-- Increases KRYSTEXXA®(pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ...

author_avatar
NASDAQ Market News